1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin, 2018, 68(1): 7-30.
|
2. |
Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet, 2016, 293(2): 247-269.
|
3. |
Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
|
4. |
Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl), 2016, 10: 25-36.
|
5. |
刘雁冰, 杨涛, 张朝蓬, 等. 乳腺癌新辅助化疗后原发肿瘤退缩模式预测列线图的建立. 吉林大学学报 (医学版), 2014, 40(6): 1319-1324.
|
6. |
曹志宇, 何建苗, 杨波, 等. 局部晚期乳腺癌新辅助化疗联合保乳手术的临床疗效观: 附 81 例报告. 解放军医学杂志, 2015, 40(6): 488-491.
|
7. |
吕文芝, 丁波泥, 钱立元, 等. 保留乳房手术对比乳房根治术治疗三阴性乳腺癌疗效的 Meta 分析. 中华乳腺病杂志 (电子版), 2018, 12(5): 276-281.
|
8. |
Gangi A, Chung A, Mirocha J, et al. Breast-conserving therapy for triple-negative breast cancer. JAMA Surg, 2014, 149(3): 252-258.
|
9. |
Zumsteg ZS, Morrow M, Arnold B, et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol, 2013, 20(11): 3469-3476.
|
10. |
Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 2007, 13(8): 2329-2334.
|
11. |
Wheate NJ, Collins JG. Multi-nuclear platinum complexes as anti-cancer drugs. Coordin Chem Rev, 2017, 241(1-2): 133-145.
|
12. |
Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Canc Netw, 2017, 15(4): 433-451.
|
13. |
Shimada H, Ueda S, Saeki T, et al. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for stage Ⅱ/Ⅲ HER2-negative breast cancer: evaluation of efficacy and safety. Jpn J Clin Oncol, 2015, 45(7): 642-649.
|
14. |
Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol, 2016, 17(3): 345-356.
|
15. |
Isakoff SJ, Mayer EL, He L, et al. TBCRC009: A multicenter phase Ⅱ clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol, 2015, 33(17): 1902-1909.
|
16. |
Litton J, Rugo HS, Ettl J, et al. Abstract GS6-07: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicians’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. Cancer Res, 2018, 78(4 Suppl): Abstract GS6-07.
|
17. |
Sharma P, López-Tarruella S, García-Saenz JA, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts. Clin Cancer Res, 2017, 23(3): 649-657.
|
18. |
Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol, 2015, 33(4): 304-311.
|
19. |
Tutt A, Robson M, Garber JE, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, 2010, 376(9737): 235-244.
|
20. |
Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol, 2018, 19(4): 497-509.
|
21. |
Chen L, Zhang J, Chen J, et al. Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes. Oncotarget, 2017, 8(26): 42917-42925.
|
22. |
罗佳宁, 郝春成, 张建鑫, 等. 术后辅助放疗对三阴性乳腺癌患者预后的影响. 实用肿瘤学杂志, 2017, 31(5): 411-416.
|
23. |
Kindts I, Buelens P, Laenen A, et al. Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival. Breast, 2017, 32: 18-25.
|
24. |
Steward LT, Gao F, Taylor MA, et al. Impact of radiation therapy on survival in patients with triple-negative breast cancer. Oncol Lett, 2014, 7(2): 548-552.
|
25. |
Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat, 2018, 167(3): 671-686.
|
26. |
Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ⅰb KEYNOTE-012 study. J Clin Oncol, 2016, 34(21): 2460-2467.
|
27. |
Adams S, Diamond JR, Hamilton E, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol, 2019, 5(3): 334-342.
|
28. |
Ali HR, Glont SE, Blows FM, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol, 2015, 26(7): 1488-1493.
|
29. |
Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res, 2014, 2(4): 361-370.
|
30. |
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med, 2018, 379(22): 2108-2121.
|
31. |
Schmid P, Chui SY, Emens LA. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. Reply. N Engl J Med, 2019, 380(10): 987-988.
|
32. |
Cortés J, André F, Gonçalves A, et al. IMpassion132 phase Ⅲ trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol, 2019, 15(17): 1951-1961.
|
33. |
Yang Q, Xu ZH, Zheng LP, et al. Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint in hibitor. Am J Cancer Res, 2018, 8(9): 1689-1696.
|
34. |
Stringer-Reasor EM, Yang ESH, May JE, et al. An open label, pilot study of veliparib (ABT-888) and lapatinlb in patients with metastatic triple-negative (ER, PR, and HER-2 negative) breast cancer. J Clin Oncol, 2018, 36(suppl 15): 1095.
|
35. |
Dent R, Im SA, Espie M, et al. Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT)+paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (m TNBC). J Clin Oncol, 2018, 36(suppl 15): 1008.
|
36. |
Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol, 2017, 18(10): 1360-1372.
|
37. |
Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol, 2018, 36(9): 884-890.
|
38. |
Lyons T, Gucalp A, Arumov A, et al. Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer. J Clin Ocol, 2018, 36(suppl 15): 531.
|